老虎证券

BUZZ-Amneal rises after US FDA greenlights self-administered migraine treatment

Reuters
2025/05/15
BUZZ-Amneal rises after US FDA greenlights self-administered migraine treatment

** Shares of drugmaker Amneal Pharmaceuticals AMRX.O rise 5.5% to $7.75 premarket

** Co says U.S. FDA has approved its self-administered migraine drug, Brekiya

** Brekiya will be available in U.S. by second half of 2025, co says

** Up to last close, stock down 7.2% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10